Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells

Vaccine

Volumn 23, Issue 33, 2005, Pages 4219-4227

  Prikazsky, Viktor ^a   Leroux Roels, Geert ^b   Van Damme, Pierre ^c   Safary, Assad ^d   Colau, Brigitte ^d   Duchene, Michel ^d  

^a Slovak National Commission for Certification of the Polio Eradication   (Slovakia)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

MRC 5 cells; Oral polio vaccine; Primary monkey kidney cells

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN; CELL STRAIN MRC 5; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EXCRETION; GASTROENTERITIS; HUMAN; HUMAN CELL; IMMUNOGENICITY; INDUSTRIAL PRODUCTION; INFANT; KIDNEY CELL; MONKEY; MOUSE; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION MAPPING; REVERTANT; SEROTYPE; TRANSGENIC MOUSE; VACCINATION; VACCINE PRODUCTION; VIRULENCE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELLS, CULTURED; CHILD; HAPLORHINI; HUMANS; KIDNEY; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; SAFETY;

EID: 22144448491     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.04.002     Document Type: Article

References (26)

1. H. Horie, M. Miyazawa, O. Yoshihiro, K. Wakabayashi, H. Yoshida, and Y. Doi Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells Vaccine 19 2001 1459 1465
2. K.M. Chumakov, E.M. Dragunsky, L.P. Norwood, M.P. Douthitt, Y. Ran, and R.E. Taffs Consistent selection of mutations in the 5′-untranslated region of oral poliovirus vaccine upon passaging in vitro J Med Virol 42 1994 79 85
3. © non coding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype J Virol 63 1989 1302 1309
4. C. Christodoulou, F. Colber-Garapin, A. Macadam, L.F. Taffs, S. Marsden, and P.D. Minor Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature J Virol 64 1990 4922 4929
5. S.R. Pollard, G. Dunn, N. Cammack, P.D. Minor, and J.W. Almond Nucleotide sequence of a neurovirulent variant of the Type 2 oral poliovirus vaccine J Virol 63 1989 4949 4951
6. © noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity Virology 181 1991 451 458
7. A.J. Cann, G. Stanway, P.J. Hugues, P.D. Minor, D.M.A. Evans, and G.C. Schild Reversion to neurovirulence of the live attenuated Sabin type 3 oral poliovirus vaccine Nucleic Acids Res 12 1984 7787 7792
8. D.M.A. Evans, G. Dunn, P.D. Minor, G.C. Schild, A.J. Cann, and G. Stanway Increased neurovirulence associated with a single nucleotide change in a non-coding region of the Sabin type 3 poliovaccine genome Nature 314 1985 548 550
9. G.D. Westrop, K.A. Wareham, D.M.A. Evans, G. Dunn, P.D. Minor, and D.I. Magrath Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine J Virol 63 1989 1338 1344
10. E. Dragunsky, R. Taffs, Y. Chernokhvostova, T. Nomora, K. Hioki, and K. Gardner A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine Biologicals 24 1996 77 86
11. K.M. Chumakov, L.B. Powers, K.E. Noonan, I.B. Roninson, and I.S. Levenbook Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine Proc Natl Acad Sci USA 88 1991 199 203
12. P.D. Minor, A. John, M. Ferguson, and J.P. Icenogle Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee J Gen Virol 67 1986 693 706
13. P.D. Minor, and G. Dunn The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut J GenVirol 69 1988 1091 1096
14. G. Dunn, N.T. Begg, W. Cammack, and P.D. Minor Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources J Med Virol 32 1990 92 95
15. WHO requirements for poliomyelitis vaccine (oral). In: World Health Organization Technical Report Series, vol. 800. World Health Organization; 1990. Annex 1.
16. WHO requirements for poliomyelitis vaccine (oral). In: World Health Organization Technical Report Series, vol. 897. World Health Organization; 2000. Annex 2.
17. WHO recommendations for the production and control of poliomyelitis vaccine (oral). In: World Health Organization Technical Report Series, vol. 904. World Health Organization; 2002. Annex 1.
18. WHO recommendations for the production and control of poliomyelitis vaccine (oral). In: World Health Organization Technical Report Series, vol. 910. World Health Organization; 2002. Annex 1.
19. Chumakov KM, Mutant Analysis by PCR and Restriction Enzyme Cleavage (MAPREC) for oral poliovirus (Sabin) vaccine. Standard Operating Procedure prepared for the WHO collaborative study on MAPREC. Version 3.4, October 2000.
20. P. Albrecht, J.C. Enterline, E.J. Boone, and M.J. Klutch Poliovirus and polio antibody assay in Hep-2 and Vero cell cultures J Biol Stand 11 1983 91 97
21. H.M. Gelfand, J.P. Fox, D.R. LeBlanc, and L. Elveback Studies on the development of natural immunity to poliomyelitis in Louisiana. V. Passive transfer of polio antibody from mother to fetus, and natural decline and disappearance of antibody in the infant J Immunol 85 1960 46 55
22. S.A. Plotkin Immunologic correlates of protection induced by vaccination Pediatr Infect Dis J 20 2001 63 73
23. K. Chumakov, L. Norwood, M. Parker, E. Dragunsky, R. Taffs, and Y. Ran Assessment of the viral DNA sequence heterogenicity for control of OPV neurovirulence Dev Biol Stand 26 1993 289 297
24. L. Mallet, F. Pelloquin, M. Brigaud, P. Caudrelier, R. Bandet, and C. Xueref Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on Vero cells or on primary monkey kidney cells J. Med Virol 52 1997 50 60
25. C. Chezzi, C.J. Dommann, N.K. Blackburn, E. Maselesele, J. McAnerney, and B.D. Schoub Genetic stability of oral polio vaccine prepared on primary monkey kidney cells or Vero cells-effects of passage in cell culture and the human gastrointestinal tract Vaccine 16 1998 2031 2038
26. Global polio eradication initiative, strategic plan 2004-2008 Wkly Epidemiol Rec 79 6 2000 55 57